Alliancebernstein L.P. Cabaletta Bio, Inc. Transaction History
Alliancebernstein L.P.
- $287 Billion
- Q3 2024
A detailed history of Alliancebernstein L.P. transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 64,630 shares of CABA stock, worth $149,295. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,630
Previous 64,630
-0.0%
Holding current value
$149,295
Previous $483,000
36.85%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CABA
# of Institutions
126Shares Held
44.8MCall Options Held
202KPut Options Held
110K-
Black Rock Inc. New York, NY4.76MShares$11 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY4.12MShares$9.52 Million0.1% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.67MShares$8.49 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.04MShares$7.01 Million0.03% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.76MShares$6.38 Million2.34% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $67M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...